SE9401351D0 - A method for diagnosis - Google Patents

A method for diagnosis

Info

Publication number
SE9401351D0
SE9401351D0 SE9401351A SE9401351A SE9401351D0 SE 9401351 D0 SE9401351 D0 SE 9401351D0 SE 9401351 A SE9401351 A SE 9401351A SE 9401351 A SE9401351 A SE 9401351A SE 9401351 D0 SE9401351 D0 SE 9401351D0
Authority
SE
Sweden
Prior art keywords
pct
sec
human
date
individual
Prior art date
Application number
SE9401351A
Other languages
English (en)
Inventor
Per Venge
Original Assignee
Venge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401351(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Venge filed Critical Venge
Priority to SE9401351A priority Critical patent/SE9401351D0/sv
Publication of SE9401351D0 publication Critical patent/SE9401351D0/sv
Priority to DE69521608T priority patent/DE69521608T2/de
Priority to AT95917540T priority patent/ATE202849T1/de
Priority to JP52758295A priority patent/JP3544544B2/ja
Priority to EP95917540A priority patent/EP0756708B1/en
Priority to DK95917540T priority patent/DK0756708T3/da
Priority to US08/722,054 priority patent/US6136526A/en
Priority to PCT/SE1995/000439 priority patent/WO1995029404A1/en
Priority to ES95917540T priority patent/ES2160709T3/es
Priority to AU23551/95A priority patent/AU2355195A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9401351A 1994-04-21 1994-04-21 A method for diagnosis SE9401351D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis
AU23551/95A AU2355195A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
ES95917540T ES2160709T3 (es) 1994-04-21 1995-04-21 Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.
JP52758295A JP3544544B2 (ja) 1994-04-21 1995-04-21 診断マーカーとしてのヒト好中球リポカリン（ｈｎｌ）の使用および抗−ｈｎｌ−抗体調製物
AT95917540T ATE202849T1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung
DE69521608T DE69521608T2 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
EP95917540A EP0756708B1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
DK95917540T DK0756708T3 (da) 1994-04-21 1995-04-21 Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat
US08/722,054 US6136526A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation
PCT/SE1995/000439 WO1995029404A1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Publications (1)

Publication Number Publication Date
SE9401351D0 true SE9401351D0 (sv) 1994-04-21

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Country Status (10)

Country Link
US (1) US6136526A (sv)
EP (1) EP0756708B1 (sv)
JP (1) JP3544544B2 (sv)
AT (1) ATE202849T1 (sv)
AU (1) AU2355195A (sv)
DE (1) DE69521608T2 (sv)
DK (1) DK0756708T3 (sv)
ES (1) ES2160709T3 (sv)
SE (1) SE9401351D0 (sv)
WO (1) WO1995029404A1 (sv)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039583A1 (en) * 1998-12-28 2000-07-06 Kabushiki Kaisya Advance System for identifying microorganism
FI115165B (sv) 2001-06-04 2005-03-15 Aboatech Ab Oy Metod för att bestämma arten av en infektion
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
ES2330005T5 (es) * 2003-03-27 2018-06-20 Children's Hospital Medical Center Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US20090197280A1 (en) 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US20100210031A2 (en) * 2006-08-07 2010-08-19 Antibodyshop A/S Diagnostic Test to Exclude Significant Renal Injury
EP2137538B1 (en) 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
JP2011503587A (ja) * 2007-11-15 2011-01-27 バイオポルト ディアグノスティックス エイ／エス 独特の分子形態を有するタンパク質バイオマーカーの診断における使用
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
KR101939964B1 (ko) 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
CN106442984B (zh) 2010-04-21 2020-03-13 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CA2863819C (en) 2012-02-09 2021-11-23 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN111624346A (zh) 2014-08-14 2020-09-04 米密德诊断学有限公司 用于预测及/或决定预后的套组
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3221340B1 (en) * 2014-11-19 2024-05-22 P & M Venge AB Diagnostic method employing human neutrophil lipocalin (hnl)
CA2968650A1 (en) * 2014-12-11 2016-06-16 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
WO2018001932A1 (en) 2016-06-30 2018-01-04 Koninklijke Philips N.V. Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3519833B1 (en) 2016-09-29 2024-08-14 MeMed Diagnostics Ltd. Methods of prognosis and treatment
EP3519834A4 (en) 2016-09-29 2020-06-17 MeMed Diagnostics Ltd. RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN121219586A (zh) 2023-06-01 2025-12-26 瑞典诊断开发有限公司 同源二聚体hnl的特异性检测
CN119375492B (zh) * 2024-12-27 2025-05-30 北京水木翼锋诊断技术有限公司 Hnl在制备用于鉴定血流感染的试剂中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
ES2160709T3 (es) 2001-11-16
WO1995029404A1 (en) 1995-11-02
US6136526A (en) 2000-10-24
DE69521608D1 (de) 2001-08-09
JP3544544B2 (ja) 2004-07-21
JPH09512630A (ja) 1997-12-16
ATE202849T1 (de) 2001-07-15
AU2355195A (en) 1995-11-16
EP0756708B1 (en) 2001-07-04
DE69521608T2 (de) 2002-05-08
EP0756708A1 (en) 1997-02-05
DK0756708T3 (da) 2001-10-29

Similar Documents

Publication Publication Date Title
SE9401351D0 (sv) A method for diagnosis
Isaza‐Guzmán et al. Salivary levels of NLRP3 inflammasome‐related proteins as potential biomarkers of periodontal clinical status
Zahavi et al. Enhanced in vivo platelet “release reaction” in old healthy individuals
Plagnat et al. Elastase, α2‐macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis
Toeller et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study
Kaldahl et al. Relationship of gingival bleeding, gingival suppuration, and supragingival plaque to attachment loss
Johnson et al. Detection of high‐risk groups and individuals for periodontal diseases: Evidence for the existence of high‐risk groups and individuals and approaches to their detection
Grbic et al. Risk indicators for future clinical attachment loss in adult periodontitis. Patient variables
Oringer et al. C‐Telopeptide pyridinoline cross‐links (ICTP (and periodontal pathogens associated with endosseous oral implants
DK0792458T3 (da) Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau
Witzel et al. Reconstructing impairment of secretory ameloblast function in porcine teeth by analysis of morphological alterations in dental enamel
JP7245174B2 (ja) 唾液のｈｇｆ及びｍｍｐ－８に基づく歯周炎の診断
Ralls et al. Problems in identifying “bursts” of periodontal attachment loss
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
Melamed et al. Type A behavior, tension, and ambulatory cardiovascular reactivity in workers exposed to noise stress.
Gupta et al. The influence of type 2 diabetes mellitus on salivary matrix metalloproteinase-8 levels and periodontal parameters: a study in an Indian population
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
Best et al. Reliability of attachment loss measurements in a longitudinal clinical trial
Rudra Mohan et al. The effect of nonsurgical periodontal therapy on pentraxin 3 levels in smokers and nonsmokers with chronic periodontitis
Matthijs et al. Intra‐examiner reproducibility of 4 dental plaque indices
AU635050B2 (en) Method for diagnosis of periodontal disease by detection of alanine aminotransferase
Lachmann et al. Reliability of findings around healthy implants in association with oral hygiene measures: A clinical, microbiological, and immunological follow‐up in edentulous patients
Santavirta et al. Sense of coherence and outcome of low-back surgery: 5-year follow-up of 80 patients
Hansen et al. Determinants of 24-h blood pressure in IDDM patients
Herrmann et al. Microassay for the detection of elastase activity in the gingival crevice